Eledon Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On January 13, 2026, the Company completed the issuance of 395,964 shares of its common stock, $0.001 par value per share, to a life sciences-focused lending partner in settlement of a cancellation fee payable to the third party in the amount of $591,393. The shares were sold pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.